Analysts expect that Avadel Pharmaceuticals PLC. (NASDAQ:AVDL) will report earnings of $0.01 per share for the current fiscal quarter, according to Zacks. Two analysts have made estimates for Avadel Pharmaceuticals PLC.’s earnings, with the lowest EPS estimate coming in at ($0.10) and the highest estimate coming in at $0.12. Avadel Pharmaceuticals PLC. posted earnings per share of ($0.54) in the same quarter last year, which suggests a positive year over year growth rate of 101.9%. The firm is scheduled to report its next earnings results on Monday, November 6th.
On average, analysts expect that Avadel Pharmaceuticals PLC. will report full year earnings of $1.18 per share for the current year, with EPS estimates ranging from $1.08 to $1.35. For the next fiscal year, analysts expect that the firm will post earnings of $0.17 per share, with EPS estimates ranging from ($0.55) to $0.89. Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research analysts that cover Avadel Pharmaceuticals PLC..
Avadel Pharmaceuticals PLC. (NASDAQ:AVDL) last posted its earnings results on Tuesday, August 8th. The company reported $0.19 EPS for the quarter, topping analysts’ consensus estimates of $0.05 by $0.14. The firm had revenue of $46.30 million during the quarter, compared to analysts’ expectations of $45.17 million. Avadel Pharmaceuticals PLC. had a net margin of 21.13% and a return on equity of 29.84%. The business’s revenue for the quarter was up 19.0% compared to the same quarter last year.
A number of equities research analysts recently weighed in on AVDL shares. Zacks Investment Research raised shares of Avadel Pharmaceuticals PLC. from a “hold” rating to a “buy” rating and set a $12.00 target price on the stock in a research note on Monday, July 17th. Langenberg & Company restated a “buy” rating and set a $30.00 price target (up previously from $27.00) on shares of Avadel Pharmaceuticals PLC. in a research report on Thursday, September 7th. Ladenburg Thalmann Financial Services raised their price objective on Avadel Pharmaceuticals PLC. from $27.00 to $30.00 in a report on Thursday, September 7th. Finally, Roth Capital set a $15.00 target price on Avadel Pharmaceuticals PLC. and gave the stock a “buy” rating in a research report on Wednesday, August 9th.
Avadel Pharmaceuticals PLC. (NASDAQ AVDL) traded up 4.19% during trading on Thursday, reaching $11.20. 123,837 shares of the company were exchanged. The firm’s 50-day moving average is $9.30 and its 200 day moving average is $9.78. Avadel Pharmaceuticals PLC. has a one year low of $8.14 and a one year high of $13.25. The company has a market capitalization of $448.94 million, a P/E ratio of 12.17 and a beta of 1.47.
In related news, insider Phillandas T. Thompson acquired 5,000 shares of the stock in a transaction on Wednesday, September 13th. The stock was purchased at an average price of $9.36 per share, for a total transaction of $46,800.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Michael S. Anderson acquired 4,000 shares of the stock in a transaction on Tuesday, September 12th. The stock was bought at an average price of $9.80 per share, with a total value of $39,200.00. The disclosure for this purchase can be found here. Insiders have bought 46,855 shares of company stock worth $445,058 over the last ninety days. Insiders own 5.07% of the company’s stock.
Large investors have recently added to or reduced their stakes in the company. Public Employees Retirement System of Ohio grew its holdings in shares of Avadel Pharmaceuticals PLC. by 37.2% in the second quarter. Public Employees Retirement System of Ohio now owns 57,690 shares of the company’s stock worth $636,000 after purchasing an additional 15,657 shares during the last quarter. Arrowstreet Capital Limited Partnership purchased a new position in shares of Avadel Pharmaceuticals PLC. in the second quarter worth $181,000. State Street Corp raised its holdings in Avadel Pharmaceuticals PLC. by 1.7% during the 2nd quarter. State Street Corp now owns 31,782 shares of the company’s stock valued at $351,000 after buying an additional 523 shares during the last quarter. Janus Henderson Group PLC bought a new stake in Avadel Pharmaceuticals PLC. during the 2nd quarter valued at $24,100,000. Finally, Stifel Financial Corp raised its holdings in Avadel Pharmaceuticals PLC. by 4.3% during the 2nd quarter. Stifel Financial Corp now owns 60,500 shares of the company’s stock valued at $667,000 after buying an additional 2,500 shares during the last quarter. 69.09% of the stock is owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION WARNING: This piece was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another website, it was stolen and reposted in violation of United States & international trademark and copyright law. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2017/09/21/flamel-technologies-s-a-avdl-expected-to-announce-earnings-of-0-01-per-share.html.
About Avadel Pharmaceuticals PLC.
Avadel Pharmaceuticals plc (NASDAQ: AVDL) is a specialty pharmaceutical company that seeks to commercialize differentiated pharmaceutical products that are safe, effective and easy to take through formulation development, by utilizing its proprietary drug delivery technology and in-licensing / acquiring new products; ultimately, helping patients adhere to their prescribed medical treatment and see better results.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Avadel Pharmaceuticals PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avadel Pharmaceuticals PLC. and related companies with MarketBeat.com's FREE daily email newsletter.